Evidence map›Paper›PMID 36994205›Full record

ArticleFrontiers in oncology2023

Diagnostic performance of integrated whole-body

Xuetao Chen, Tingting Yuan, Maomao Wei, Boqi Yu, Nina Zhou, Hua Zhu, Zhi Yang, Xuejuan Wang

2 registry-linked trialsOpen access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05004961 unknown statusnot on this map

The Performance of Multi-tracer Multimodality PET in Lymphoma

TypeobservationalSponsorPeking University Cancer Hospital & InstituteRan2019 to 2023Enrolled200ConditionsPositron-Emission Tomography
NCT05390632 unknown statusnot on this map

Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas

TypeobservationalSponsorPeking University Cancer Hospital & InstituteRan2019 to 2023Enrolled100ConditionsPET/MRI
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xuetao ChenKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Tingting YuanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Maomao WeiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Boqi YuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Nina ZhouKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Hua ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Xuejuan WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Peking University · CNPeking University Cancer Hospital · CNNational Medical Products Administration · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the diagnostic performance of integrated whole-body Methods: Patients with treatment-naive indolent lymphoma who underwent integrated whole-body Results: Fifty-five patients (24 males and 31 females; mean age: 51.1 ± 10.1 years) were included in this study. Of these 55 patients, 19 (34.5%) had BMI. Two patients were upstaged as extra bone marrow lesions were detected Conclusion: Integrated whole-body Trial registration: ClinicalTrials.gov (NCT05004961 and NCT05390632).

Indexed as

bone marrow biopsybone marrow involvementindolent lymphomaintegrated whole-body 18 F-FDG PET/MRIMRIPET

Identifiers

PMID36994205
PMCPMC10040668
OpenAlexW4324086035

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read123
identifiers read2
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.